Dr. Jakubowiak Discusses the Toxicity Profile of Panobinostat in the PANORAMA Trial

Andrzej Jakubowiak, MD, PhD
Published Online: Tuesday, June 17, 2014
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.

Jakubowiak says ideally, researchers aim to create a drug or drug combination that is more active with less toxicity. In the PANORAMA trial, there was a higher proportion of GI toxicities in the panobinistat arm compared to the placebo arm. There was also a higher rate of thrombocytopenia and other hematological toxicities. However, all of the toxicities were mostly manageable and did not impact the outcome, Jakubowiak says.

More details are needed to get a better understanding of the toxicity profile of this combination in this setting, Jakubowiak says.

Online CME Activities
Free CME from PER
Update From ASCO: Advances in Immunotherapy for Non–Small Cell Lung Cancer and Melanoma
Updates in Supportive Care From ASCO 2014
Community Practice Connections: Personalization of NSCLC Therapy: Novel Breakthroughs in Patient Care
Cancer Summaries and Commentaries: Update from Chicago – Advanced Gastrointestinal Cancers
More Reading
Publications
$auto_registration$